Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
MM-141
print preview
bookmark
share with colleague
General Information
Company
Merrimack Pharmaceuticals Inc.
Description
Tetravalent antibody targeting insulin-like growth factor 1 (IGF-1) receptor (IGF1R; CD221) and epidermal growth factor receptor 3 (EGFR3; HER3; ErbB3)
Molecular Target
Epidermal growth factor receptor 3 (EGFR3) (HER3) (ErbB3)
;
Insulin-like growth factor-1 (IGF-1) receptor (IGF1R) (CD221)
Mechanism of Action
Antibody
Latest Stage of Development
Phase I
Indication
Solid tumors
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy